Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study

Nicholas Carlson; Kristine Hommel; Jonas Bjerring Olesen; Thomas Alexander Gerds; Anne Merete Boas Soja; Tina Vilsbøll Lauritsen; Anne-Lise Kamper; Christian Torp-Pedersen; Gunnar Hilmar Gislason

doi:10.1111/dom.12764

Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study

Nicholas Carlson, Kristine Hommel, Jonas Bjerring Olesen, Thomas Alexander Gerds, Anne Merete Boas Soja, Tina Vilsbøll Lauritsen, Anne-Lise Kamper, Christian Torp-Pedersen, Gunnar Hilmar Gislason

11 Citationer (Scopus)

Abstract

Recent guidelines governing anti-diabetic medications increasingly advocate metformin as first-line therapy in all patients with type 2 diabetes. However, metformin could be associated with increased risk of acute kidney injury (AKI), acute dialysis and lactate acidosis in marginal patients. In a retrospective nationwide cohort study, a total of 168 443 drug-naïve patients with type 2 diabetes ≥50 years, initiating treatment with either metformin or sulphonyl in Denmark between 2000 and 2012 were included in this study (70.7% initiated treatment with metformin); calculation of 1-year risk of acute dialysis was based on g-standardization of cause-specific Cox regression models for acute dialysis, end-stage renal disease and death. One-year risks of acute dialysis were 92.4 per 100 000 (95% CI, 67.1-121.3) and 142.7 per 100 000 (95% CI, 118.3-168.0) for sulphonylurea and metformin, respectively. The metformin-associated 1-year risk of acute dialysis was increased by 50.3 per 100 000 (95% CI, 7.9-88.6), corresponding to a risk ratio of 1.53 (95% CI, 1.06-2.23), and a number needed to harm of 1988, thus providing evidence of potential concerns pertaining to the increasing use of metformin.

Originalsprog	Engelsk
Tidsskrift	Diabetes, Obesity and Metabolism
Vol/bind	18
Udgave nummer	12
Sider (fra-til)	1283-1287
Antal sider	5
ISSN	1462-8902
DOI	https://doi.org/10.1111/dom.12764
Status	Udgivet - 1 dec. 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1111/dom.12764

Citationsformater

@article{fbc40d2543304599872e1d4976a5e328,

title = "Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study",

abstract = "Recent guidelines governing anti-diabetic medications increasingly advocate metformin as first-line therapy in all patients with type 2 diabetes. However, metformin could be associated with increased risk of acute kidney injury (AKI), acute dialysis and lactate acidosis in marginal patients. In a retrospective nationwide cohort study, a total of 168 443 drug-na{\"i}ve patients with type 2 diabetes ≥50 years, initiating treatment with either metformin or sulphonyl in Denmark between 2000 and 2012 were included in this study (70.7% initiated treatment with metformin); calculation of 1-year risk of acute dialysis was based on g-standardization of cause-specific Cox regression models for acute dialysis, end-stage renal disease and death. One-year risks of acute dialysis were 92.4 per 100 000 (95% CI, 67.1-121.3) and 142.7 per 100 000 (95% CI, 118.3-168.0) for sulphonylurea and metformin, respectively. The metformin-associated 1-year risk of acute dialysis was increased by 50.3 per 100 000 (95% CI, 7.9-88.6), corresponding to a risk ratio of 1.53 (95% CI, 1.06-2.23), and a number needed to harm of 1988, thus providing evidence of potential concerns pertaining to the increasing use of metformin.",

keywords = "Journal Article",

author = "Nicholas Carlson and Kristine Hommel and Olesen, {Jonas Bjerring} and Gerds, {Thomas Alexander} and Soja, {Anne Merete Boas} and Lauritsen, {Tina Vilsb{\o}ll} and Anne-Lise Kamper and Christian Torp-Pedersen and Gislason, {Gunnar Hilmar}",

note = "{\textcopyright} 2016 John Wiley & Sons Ltd.",

year = "2016",

month = dec,

day = "1",

doi = "10.1111/dom.12764",

language = "English",

volume = "18",

pages = "1283--1287",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "12",

}

TY - JOUR

T1 - Metformin-associated risk of acute dialysis in patients with type 2 diabetes

T2 - A nationwide cohort study

AU - Carlson, Nicholas

AU - Hommel, Kristine

AU - Olesen, Jonas Bjerring

AU - Gerds, Thomas Alexander

AU - Soja, Anne Merete Boas

AU - Lauritsen, Tina Vilsbøll

AU - Kamper, Anne-Lise

AU - Torp-Pedersen, Christian

AU - Gislason, Gunnar Hilmar

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Recent guidelines governing anti-diabetic medications increasingly advocate metformin as first-line therapy in all patients with type 2 diabetes. However, metformin could be associated with increased risk of acute kidney injury (AKI), acute dialysis and lactate acidosis in marginal patients. In a retrospective nationwide cohort study, a total of 168 443 drug-naïve patients with type 2 diabetes ≥50 years, initiating treatment with either metformin or sulphonyl in Denmark between 2000 and 2012 were included in this study (70.7% initiated treatment with metformin); calculation of 1-year risk of acute dialysis was based on g-standardization of cause-specific Cox regression models for acute dialysis, end-stage renal disease and death. One-year risks of acute dialysis were 92.4 per 100 000 (95% CI, 67.1-121.3) and 142.7 per 100 000 (95% CI, 118.3-168.0) for sulphonylurea and metformin, respectively. The metformin-associated 1-year risk of acute dialysis was increased by 50.3 per 100 000 (95% CI, 7.9-88.6), corresponding to a risk ratio of 1.53 (95% CI, 1.06-2.23), and a number needed to harm of 1988, thus providing evidence of potential concerns pertaining to the increasing use of metformin.

AB - Recent guidelines governing anti-diabetic medications increasingly advocate metformin as first-line therapy in all patients with type 2 diabetes. However, metformin could be associated with increased risk of acute kidney injury (AKI), acute dialysis and lactate acidosis in marginal patients. In a retrospective nationwide cohort study, a total of 168 443 drug-naïve patients with type 2 diabetes ≥50 years, initiating treatment with either metformin or sulphonyl in Denmark between 2000 and 2012 were included in this study (70.7% initiated treatment with metformin); calculation of 1-year risk of acute dialysis was based on g-standardization of cause-specific Cox regression models for acute dialysis, end-stage renal disease and death. One-year risks of acute dialysis were 92.4 per 100 000 (95% CI, 67.1-121.3) and 142.7 per 100 000 (95% CI, 118.3-168.0) for sulphonylurea and metformin, respectively. The metformin-associated 1-year risk of acute dialysis was increased by 50.3 per 100 000 (95% CI, 7.9-88.6), corresponding to a risk ratio of 1.53 (95% CI, 1.06-2.23), and a number needed to harm of 1988, thus providing evidence of potential concerns pertaining to the increasing use of metformin.

KW - Journal Article

U2 - 10.1111/dom.12764

DO - 10.1111/dom.12764

M3 - Journal article

C2 - 27534835

SN - 1462-8902

VL - 18

SP - 1283

EP - 1287

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 12

ER -

Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater